首页> 外文期刊>Nature >Two disparate ligand-binding sites in the human P2Y_1 receptor
【24h】

Two disparate ligand-binding sites in the human P2Y_1 receptor

机译:人类P2Y_1受体中两个不同的配体结合位点

获取原文
获取原文并翻译 | 示例
           

摘要

In response to adenosine 5'-diphosphate, the P2Y_1 receptor (P2Y_1R) facilitates platelet aggregation, and thus serves as an important antithrombotic drug target. Here we report the crystal structures of the human P2Y_1R in complex with a nucleotide antagonist MRS2500 at 2.7 A resolution, and with a non-nucleotide antagonist BPTU at 2.2 A resolution. The structures reveal two distinct ligand-binding sites, providing atomic details of P2Y_1R's unique ligand-binding modes. MRS2500 recognizes a binding site within the seven transmembrane bundle of P2Y_1R, which is different in shape and location from the nucleotide binding site in the previously determined structure of P2Y_(12)R, representative of another P2YR subfamily. BPTU binds to an allosteric pocket on the external receptor interface with the lipid bilayer, making it the first structurally characterized selective G -protein - coupled receptor (GPCR) ligand located entirely outside of the helical bundle.These high-resolution insights into P2Y_1R should enable discovery of new orthosteric and allosteric antitrombotic drugs with reduced adverse effects.%在这篇论文中,Beili Wu及同事报告了人P2Y_1受体(一种"G-蛋白耦合受体",简称GPCR)的X-射线晶体结构。同P2Y_(12)受体一样,这种膜蛋白也调控血小板激活和血栓形成。这两种GPCR都是新型抗血栓药物的研发工作的重要目标。将这一结构与一个以前发表的P2Y_(12)受体结构所做对比表明,这两种GPCR的正构配体结合点是很不相同的:P2Y_1受体的结合点要比P2Y_(12)受体的结合点浅得多。作者还获得了该蛋白在核苷酸拮抗剂MRS2500和非核苷酸拮抗剂BPTU存在时的结构。MRS2500在正构点结合,但BPTU则与GPCR/类脂双层界面上一个不寻常的袋相结合。
机译:响应于5'-二磷酸腺苷,P2Y_1受体(P2Y_1R)促进血小板聚集,因此成为重要的抗血栓药物靶标。在这里,我们报告人P2Y_1R的晶体结构与2.7 A分辨率的核苷酸拮抗剂MRS2500和2.2 A分辨率的非核苷酸拮抗剂BPTU复杂。该结构揭示了两个不同的配体结合位点,提供了P2Y_1R独特的配体结合模式的原子细节。 MRS2500识别P2Y_1R的七个跨膜束中的结合位点,其形状和位置与先前确定的P2Y_(12)R结构中的核苷酸结合位点不同,代表另一个P2YR亚家族。 BPTU与脂质双层结合在外部受体界面的变构口袋上,使其成为第一个完全位于螺旋束外部的结构特征选择性G蛋白偶联受体(GPCR)配体。这些对P2Y_1R的高分辨率洞察力应能降低不良反应的正构和变构抗绒毛性新药的发现。%在本文中,Beili Wu及同事报告了人P2Y_1受体(一种“ G蛋白受体”,简称GPCR)的X射线晶体结构。同P2Y_(12)受体一样,这种膜蛋白也被碎片活化和血栓形成。这两种GPCR都是新型抗血栓药物的研发工作的重要目标。将这一结构与一个以前发表的P2Y_。 (12)受体结构协同对比表明,这两种GPCR的正构配体结合点是很不相同的:P2Y_1受体的结合点要比P2Y_(12)受体的结合点浅一点。 MRS2500在正构点结合,但BPTU则与GPCR /类脂双层界面上一个不寻常的袋相结合。

著录项

  • 来源
    《Nature》 |2015年第7547期|317-321c3|共6页
  • 作者单位

    CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

    Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA;

    CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

    Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA;

    Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA;

    CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

    Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA;

    CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

    CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

    CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

    Bridge Institute, Department of Chemistry, University of Southern California, Los Angeles, California 90089, USA;

    CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

    Bridge Institute, Department of Chemistry, University of Southern California, Los Angeles, California 90089, USA;

    Bridge Institute, Department of Biological Sciences, University of Southern California, Los Angeles, California 90089, USA;

    Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

    Bridge Institute, Department of Chemistry, University of Southern California, Los Angeles, California 90089, USA,Bridge Institute, Department of Biological Sciences, University of Southern California, Los Angeles, California 90089, USA,iHuman Institute, ShanghaiTech University, 99 Haike Road, Pudong, Shanghai 201203, China;

    Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA;

    CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

    CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号